- ICH GCP
- US Clinical Trials Registry
- Search trials
Clinical Trials on Cancer Patients With PICC in Hungary
Total 18 results
-
Dr. Gergő MolnárSemmelweis University Heart and Vascular Center; Petz Aladar County Teaching... and other collaboratorsUnknownDiabetic Patients With/Without Atherosclerotic DiseasesHungary
-
AllecraCompletedPK in Patients With Various Degrees of Renal ImpairmentCzechia, Hungary
-
National Institute of Oncology, HungaryRecruitingQuality of Life | Breast Cancer | Patient SatisfactionHungary
-
National Institute of Oncology, HungaryRecruitingQuality of Life | Breast Cancer | Patient Satisfaction | Mastectomy; LymphedemaHungary
-
University of PecsRecruitingWaiting Times, Patient Pathways, Effect of Lifestyle-related, Clinical and Demographic Parameters on OutcomesHungary
-
AstraZenecaCompletedCaucasian Patients With EGFR Mutation Positive Advanced NSCLCBulgaria, Italy, Poland, Spain, Turkey, United Kingdom, Romania, Norway, Hungary, Portugal, Greece, Switzerland, France
-
PfizerTerminatedAvelumab in Combination With Talazoparib Will be Investigated in Patients With Locally Advanced (Primary or Recurrent) or Metastatic Solid TumorsUnited States, Canada, United Kingdom, Korea, Republic of, Australia, Belgium, Denmark, Hungary, Russian Federation
-
Solvay PharmaceuticalsCompletedPatients With Metabolic SyndromeHungary, Canada, Finland, Italy, Netherlands, Norway, Poland, Romania, Sweden
-
Novartis PharmaceuticalsCompletedTreatment of Early Pulmonary Infections With P. Aeruginosa in Cystic Fibrosis PatientsEgypt, Greece, Hungary, Russian Federation, Canada, Germany, France, Italy, Switzerland, Romania
-
AmgenCompletedBone Metastases in Men With Hormone-Refractory Prostate Cancer | Bone Metastases in Subjects With Advanced Breast CancerSpain, Czechia, Peru, Russian Federation, Austria, Lithuania, Poland, South Africa, Italy, Ukraine, Israel, Argentina, Belgium, Brazil, France, Hungary, Japan, Latvia, Panama
-
AstraZenecaCompletedBRCA or HRR+ Mutated Ovarian Cancer PatientsItaly, Spain, Canada, Czechia, Poland, United Kingdom, Hungary, Bulgaria
-
Otsuka Pharmaceutical Development & Commercialization...RecruitingAgitation in Patients With Dementia of the Alzheimer's TypeUnited States, Belgium, Canada, Chile, Colombia, Croatia, Hungary, Mexico, Netherlands, Slovakia, Slovenia, Spain, Ireland
-
Galena Biopharma, Inc.CompletedBreast Cancer With Low to Intermediate HER2 ExpressionUnited States, United Kingdom, France, Israel, Germany, Canada, Russian Federation, Romania, Bulgaria, Czech Republic, Hungary, Poland, Ukraine
-
Otsuka Pharmaceutical Development & Commercialization...CompletedAgitation in Patients With Dementia of the Alzheimer's TypeSpain, United States, Italy, United Kingdom, Hungary, France, Poland, Australia, Bulgaria, Czechia, South Africa
-
NantCell, Inc.TakedaTerminatedCancer | Pancreatic Cancer | Advanced Solid Tumors | Metastatic Cancer | Bone Metastases | Solid Tumors | Pancreas Cancer | Adenocarcinoma of the Pancreas | Oncology | Cancer of Pancreas | Metastatic Pancreatic Cancer | Metastases | Cancer of the Pancreas | Advanced Malignancy | Oncology Patients | Endocrine CancerItaly, Spain, United Kingdom, Belgium, Canada, Denmark, Romania, United States, Germany, Netherlands, Korea, Republic of, Russian Federation, Australia, Austria, Lithuania, Portugal, Greece, Poland, Switzerland, Serbia, Bulgaria, ... and more
-
BayerActive, not recruitingHot Flashes | Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast CancerSpain, France, Belgium, United Kingdom, Hungary, Israel, Italy, Ireland, Germany, Portugal, Finland, Poland, Romania, Canada, Austria, Kazakhstan
-
Otsuka Pharmaceutical Development & Commercialization...RecruitingAgitation in Patients With Dementia of the Alzheimer's TypeUnited States, Spain, Hungary, Italy, Canada, Czechia, South Africa, Bulgaria, France, Poland
-
Novartis PharmaceuticalsActive, not recruitingLocally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutationSpain, Italy, Austria, Netherlands, United Kingdom, Germany, Thailand, France, Belgium, China, Argentina, Greece, Turkey, Malaysia, Portugal, Hungary, Brazil, United States, India